- Alnylam’s revenue for the fourth quarter reached $593.2 million, which is a 35% increase year-over-year and exceeded the estimate of $585 million.
- The company reported a loss per share of 65 cents, an improvement from a loss of $1.10 per share the previous year, close to the estimated loss of 64 cents per share.
- Net product revenues totaled $450.8 million, marking a 30% increase year-over-year, surpassing the estimates of $439.8 million.
- Onpattro’s net product revenues fell to $56.1 million, a decline of 29% year-over-year, but slightly above the estimate of $55.3 million.
- Givlaari’s net product revenues increased by 9% year-over-year to $64.6 million, falling short of the estimated $69.8 million.
- Oxlumo’s net product revenues were $43.6 million, an increase of 33% year-over-year, nearly meeting the estimate of $43.9 million.
- Collaboration revenue grew by 40% year-over-year to $106.9 million, though it did not meet the estimate of $115.9 million.
- Operating expenses rose 26% year-over-year to $698.3 million, higher than the estimated $630.7 million.
- The company holds $966.4 million in cash and cash equivalents, a 19% increase year-over-year, but below the estimated $1.16 billion.
- AMVUTTRA’s net product revenue surged by 63% year-over-year to $286.5 million, surpassing the estimate of $273.9 million.
- Alnylam anticipates significant advancements in 2025, with plans for over 25 high-value programs in clinical development across various indications by the end of the year.
- Analyst ratings include 22 buy recommendations, 8 holds, and 2 sells.
“`
Alnylam Pharmaceuticals on Smartkarma
Analyst coverage of Alnylam Pharmaceuticals on Smartkarma delves into the company’s significant growth and expansion in its product and pipeline portfolios. Baptista Research, a key provider on Smartkarma, highlights Alnylam’s strong financial performance in Q3 2024, with a remarkable 34% year-over-year increase in global net product revenue, amounting to $420 million. The success is largely credited to the exceptional performance of its TTR franchise, which saw a 34% increase from the previous year, generating $309 million. This expansion, particularly in neurodegenerative diseases, is identified as a pivotal factor propelling Alnylam’s growth.
A look at Alnylam Pharmaceuticals Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Alnylam Pharmaceuticals Inc., an early-stage therapeutics company, is poised for long-term success based on its strong Smartkarma Smart Scores. With a Growth score of 4 and a Resilience score of 5, the company demonstrates promising potential for expansion and stability. Their focus on developing technology to silence disease-causing genes sets them apart in the pharmaceutical industry, indicating innovative solutions to medical challenges.
While Alnylam Pharmaceuticals may have lower scores in Value and Dividend, the Momentum score of 4 reflects positive market sentiment and confidence in the company’s future performance. Investors may find Alnylam Pharmaceuticals an attractive option for long-term growth and innovation in the field of therapeutics, as indicated by the overall favorable Smartkarma Smart Scores.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
